Good MorningEquity markets were flat on Wednesday as markets digested the previous day's gains. The S&P hovered near an all-time high and may move up to set a new high soon, but there is risk. The rally has become long in the tooth and ready to correct. The S&P 500 is setting new highs but diverging from indicators, suggesting growing weakness within the market. In this scenario, a small 5% 5o 10% correction would be healthy and set the market up to resume the rally by mid-year.
Tech continues to drag on the markets. Rallies in NVIDIA, Advanced Micro Devices, Meta Platforms, and other mega-cap tech were driving the rally but are now struggling with resistance. If these stocks can't sustain their uptrends, the S&P 500 will likely stall at current levels. With mega-caps looking overbought, investors have begun to turn to small and mid-caps where value can be found. Featured: Get our next stock pick (free service) (Ad) 
|
Stocks | | |
As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI, the murmurs of potential interest rate cuts by the Federal Reserve continue, and investors find themselves at a juncture where prudence meets opportunity.
Amid t... Read the Full Story |
|
From Our Partners | | AI technology is becoming an integral part of the financial system.
From transaction monitoring to risk assessments, artificial intelligence is increasingly influencing how banks and governments manage financial services. These changes are designed to improve security and efficiency—but they also require individuals to be more proactive about protecting their financial access.
Preparation starts with awareness. | | In a world where technology moves fast, staying informed is one of the best ways to protect your fin |
|
Stocks | | |
The world economy has gone online; there is no turning back from this fact. The only question is how you can profit from this transition. Because more players have become dependent on cybersecurity, the World Economic Forum (WEF) is slowly making this an important theme. Today, you can get ahead o... Read the Full Story |
|
Stocks | | |
Comcast Corp. (NASDAQ: CMCSA), Charles Schwab Corp. (NYSE: SCHW) and Alphabet Inc. (NASDAQ: GOOGL) are among institutional-quality large-cap stocks that are currently undervalued.
There are a few reasons why institutions continue showing conviction when it comes to stocks priced below where their... Read the Full Story |
|
From Our Partners | | Ready to ride the next crypto wave? Our new ebook, "Crypto Boom Strategy", shares the ETFs and stocks that experienced investors are watching, ideal for those with a moderately aggressive investment approach. | | 👉 Click here to download your free ebook now! |
|
Stocks | | |
As digital media expands and personal file collections grow, cloud computing stocks have become a major focal point for investors. This industry, vital for global connectivity and collaboration, has experienced steady growth, particularly highlighted during the ongoing digital transformation spurr... Read the Full Story |
|
Stocks | | | Asian shares mostly declined Thursday in lackluster trading after U.S. stocks drifted to a mixed finish. Japan's Nikkei 225 shed 0.2% in morning trading to 38,625.22. Nissan Motor Co. stock jumped 2.3% after an unconfirmed Japanese media report that the automaker behind the Leaf electric car was abo... Read the Full Story |
|
From Our Partners | | Wall Street’s love affair with options might be one of the biggest distractions in modern trading.
Because while retail traders chase leverage — and fight a built-in clock working against them — a quiet subset of securities is flying under the radar. They trade just like stocks, but have the potential to deliver option-like returns… without the usual decay or risk profile.
Now, for the first time, a veteran trader is revealing these “Supercharged Tickers” — and how they could offer up to 4X gains without touching options. | | if you'd like to get started on these, you best head over here now. |
|
Markets | | | Russians are finding a few imported staples, like fruit, coffee and olive oil, have shot way up in price. Most global brands have disappeared — or been reincarnated as Russian equivalents under new, Kremlin-friendly ownership. A lot more Chinese cars are zipping around the streets. Those who want a ... Read the Full Story |
|
Stocks | | |
The price action in Airship AI Holdings (NASDAQ: AISP) spiked 500% in two days, bringing it to the attention of MarketBeat's unusual trading activity sensors. The spike was accompanied by a 500X increase in volume that promises to keep this stock moving higher.
Why will AirshipAI move highe... Read the Full Story |
|
Markets | | | Dollar Tree swung to a surprise fourth-quarter loss and will close nearly 1,000 stores after the discount retailer slashed the value of a rival chain it acquired almost a decade ago.Dollar Tree plans to close about 600 Family Dollar stores in the first half of this year and 370 Family Dollar and 30 ... Read the Full Story |
|
Markets | | | Some investors in a troubled trust fund in China are facing financial ruin under a government plan to return a fraction of their money, casualties of a slump in the property industry and a broader economic slowdown. Sichuan Trust, headquartered in the southwest city of Chengdu, announced it was inso... Read the Full Story |
|
Markets | | | Japan's economy managed to grow in the fourth quarter of last year, averting a recession, according to revised government data released Monday that had previously shown a contraction.Real gross domestic product, or GDP, grew in October-December at an annual pace of 0.4% instead of a contraction of 0... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
